share_log

HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $5 Price Target

Benzinga ·  Jan 30 11:51

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spero Therapeutics (NASDAQ:SPRO) with a Buy and maintains $5 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 352
Write a comment